Gastroesophageal Junction Cancer News

News

Postoperative Adjuvant Chemotherapy Improves Survival Outcomes for Patients With Gastroesophageal Junction Adenocarcinoma

01/10/2023

According to a study, adjuvant chemotherapy after gastrectomy improved the overall survival and disease-free survival for patients with gastroesophageal junction adenocarcinoma, compared to gastrectomy alone.

According to a study, adjuvant...

01/10/2023

Oncology

News

Second-Line Anlotinib Plus Toripalimab Demonstrates Safety, Efficacy in Advanced Gastric or Gastroesophageal Junction Carcinoma

12/20/2022

Allison Casey ;

A single-arm study found that anlotinib combined with toripalimab is an effective and safe second-line treatment for patients with gastric or gastroesophageal junction carcinoma.

A single-arm study found that...

12/20/2022

Oncology

News

FLOT Chemotherapy and CROSS Trimodality Regimen Result in Equivalent Survival for Patients With Gastroesophageal Junction Adenocarcinoma

12/01/2022

Allison Casey ;

A propensity-matched comparison found that survival outcomes were equivalent for both FLOT chemotherapy regimen and the CROSS trimodality regimen among patients with gastroesophageal junction cancer.

A propensity-matched comparison...

12/01/2022

Oncology

News

Modified FLOT Improves Surgical Outcomes for Patients With Gastroesophageal Junction Adenocarcinoma

11/29/2022

Allison Casey ;

Among patients with gastroesophageal junction adenocarcinomas planned for curative resection, perioperative chemotherapy with the modified FLOT regimen was associated with improved resection rates and survival compared to the EOX regimen.

Among patients with...

11/29/2022

Oncology

News

Bemarituzumab Demonstrates Promising Clinical Efficacy in FGFR2b-Selected Gastric or GEJ Adenocarcinoma

11/03/2022

In a phase 2 trial, bemarituzumab demonstrated promising clinical efficacy, despite not reaching the primary end point of PFS, for patients with FGFR2b-selected gastric or gastroesophageal junction (GEJ) adenocarcinomas.

In a phase 2 trial,...

11/03/2022

Oncology

News

No Survival Benefit From Pertuzumab Plus Trastuzumab and Chemotherapy as First-Line Therapy for HER2-Positive Gastric/Gastroesophageal Junction Cancer

10/07/2022

Allison Casey ;

According to the final results from a phase 3 trial, there was no survival benefit from adding pertuzumab to trastuzumab and chemotherapy as a first-line therapy for patients with HER2-positive gastric or gastroesophageal junction cancer.

According to the final results...

10/07/2022

Oncology

News

The Potential for Neoadjuvant Nivolumab and Ipilimumab for Patients With Gastric or Gastroesophageal Junction Cancer

10/06/2022

In a phase 2 study, neoadjuvant nivolumab and ipilimumab followed by surgery and adjuvant nivolumab was found to be a feasible treatment option with a high pathological complete response rate in patients with gastric or gastroesophageal...

In a phase 2 study, neoadjuvant...

10/06/2022

Oncology

News

PD-L1 Expression Strong Predictor of Overall Survival Benefit From Immune Checkpoint Inhibition in Gastroesophageal Cancer

10/06/2022

Allison Casey ;

A systemic review and meta-analysis found that tissue-based PD-L1 expression is the strongest predictor of overall survival benefit from immune checkpoint inhibition for patients with advanced gastroesophageal cancer.

A systemic review and...

10/06/2022

Oncology

News

Anlotinib Plus Toripalimab Shows Promising Efficacy, Safety as Second-Line Treatment for Gastric and GEJ Carcinoma

08/04/2022

Allison Casey ;

Results of a phase 2 trial found that combined treatment with anlotinib and toripalimab showed promising efficacy and safety for gastric and gastroesophageal junction (GEJ) carcinoma in the second-line setting.

Results of a phase 2 trial found...

08/04/2022

Oncology

News

Certain Biomarkers Associated With Clinical Benefit From Tislelizumab in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

07/13/2022

Allison Casey ;

According to the results of 2 phase 1/2 trials, in advanced gastric/gastroesophageal junction adenocarcinoma PD-L1 positivity, IFNγ-related gene signatures, and TMB-high status were associated with gaining clinical benefit when treated with...

According to the results of 2...

07/13/2022

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology